Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

InhaleRx Ltd (ASX: IRX) has announced the successful completion of its first drawdown of $247,500 under its $38.5 million ...

Mineralys plans to provide additional data from the pivotal Phase 3 Launch-HTN at an upcoming medical conference and in a peer-reviewed publication. Additionally, the ongoing Transform-HTN open-label ...

Session Name: 652. Oral Abstract Session - Hematologic Malignancies-Plasma Cell Dyscrasia ...

Viking Therapeutics saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for the Phase 2 ...

AP402 targets p95HER2, a truncated form of HER2 present in 30-40% of HER2-positive cancers, which is associated with exceptionally poor prognosis, and not addressable by conventional anti-HER2 ...

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.“I’ve argued for a long time that for phase 1 ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Scientific research continues to uncover interesting connections between the gut microbiome and human health, including ...

today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5 ...